Cocrystal Pharma (COCP) vs China Pharma (CPHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cocrystal Pharma (COCP) has outperformed China Pharma (CPHI) over the past year, gaining 5.6% versus a loss of 72.6%. Over five years, COCP leads with a -91.8% price change compared with -99.8% for CPHI. China Pharma is the larger company by market cap ($18.9 million vs $18.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COCP | CPHI |
|---|---|---|
| Share price | $0.95 | $0.4384 |
| Market cap | $18.30M | $18.86M |
| 1-day change | -2.05% | -13.00% |
| YTD return | -3.06% | -63.77% |
| 1-year return | +5.56% | -72.60% |
| 5-year return | -91.84% | -99.84% |
| EPS (TTM) | $-0.76 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $4.14M |
| Revenue growth (YoY) | — | -8.49% |
| Net income (latest FY) | $-8.83M | $-3.19M |
| Gross margin | — | -3.18% |
| Operating margin | — | -78.16% |
| Net margin | — | -76.91% |
| 52-week high | $2.03 | $19.19 |
| 52-week low | $0.76 | $0.38 |
| Distance from 52-week high | -53.20% | -97.72% |
| Analyst consensus | none | — |
| Avg. price target upside | +847.37% | — |
| Average volume | 40.65K | 1.60M |
| Shares outstanding | 19.26M | 43.02M |
| Employees | 10 | 215 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COCP has outperformed CPHI by 78.2 percentage points over the past year.
About Cocrystal Pharma
COCP stock →Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees
COCP vs CPHI FAQ
Which is bigger, Cocrystal Pharma or China Pharma?
China Pharma (CPHI) is larger, with a market capitalization of $18.86M compared with $18.30M for Cocrystal Pharma (COCP).
Which stock has performed better over the past year, COCP or CPHI?
COCP returned +5.56% over the past 12 months, compared with -72.60% for CPHI (price return, excluding dividends). Past performance does not predict future results.
Are Cocrystal Pharma and China Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.